Company: ABBV
Filing Date: 2025-02-14
Form Type: 10-K
Source: 0001551152-25-000020
Chunk: 302

Company: AbbVie Inc.
Filing Date: 2025-02-14
Form: 10-K
Item: Item 8
Chunk 302
---
 equivalents$5,524 $12,814 Short-term investments31 2 Accounts receivable, net10,919 11,155 Inventories4,181 4,099 Prepaid expenses and other4,927 4,932 Total current assets25,582 33,002 Investments279 304 Property and equipment, net5,134 4,989 Intangible assets, net60,068 55,610 Goodwill34,956 32,293 Other assets9,142 8,513 Total assets$135,161 $134,711 Liabilities and EquityCurrent liabilitiesCurrent portion of long-term debt and finance lease obligations$6,804 $7,191 Accounts payable and accrued liabilities31,945 30,650 Total current liabilities38,749 37,841 Long-term debt and finance lease obligations60,340 52,194 Deferred income taxes2,579 1,952 Other long-term liabilities30,129 32,327 Commitments and contingenciesStockholders' equity Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,831,594,494 shares issued as of December 31, 2024 and 1,823,046,087 as of December 31, 202318 18 Common stock held in treasury, at cost, 66,337,508 shares as of December 31, 2024 and 57,105,354 as of December 31, 2023(8,201)(6,533)Additional paid-in capital21,333 20,180 Accumulated deficit(7,900)(1,000)Accumulated other comprehensive loss(1,925)(2,305)Total stockholders' equity3,325 10,360 Noncontrolling interest39 37 Total equity3,364 10,397 Total liabilities and equity$135,161 $134,711 

The accompanying notes are an integral part of these consolidated financial statements.

53     |  2024 Form 10-K

AbbVie Inc. and Subsidiaries

Consolidated Statements of Equity

years ended December 31 (in millions)Common shares outstandingCommon stockTreasury stockAdditional paid-in capital Retained earnings (accumulated deficit)Accumulated other comprehensive lossNoncontrolling interestTotalBalance at December